Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  REGENXBIO Inc.    RGNX

REGENXBIO INC.

(RGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

REGENXBIO : to Participate in Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
09/25/2020 | 08:01am EDT

ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will participate in the following upcoming investor conferences, which will each be held in a virtual meeting format:

SVB Leerink CybeRx Series: Rare Diseases & Genetic Medicines
Date: Thursday, October 1, 2020

Jefferies Virtual Gene Therapy/Editing Summit
Date: Friday, October 2, 2020

Chardan Virtual 4th Annual Genetic Medicines Conference
Date: Tuesday, October 6, 2020
Fireside Chat: Tuesday, October 6, 2020 at 10:30 a.m. ET

A live webcast of the Chardan fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the fireside chat webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

Cision
View original content:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301138006.html

SOURCE REGENXBIO Inc.

© PRNewswire 2020

share with twitter share with LinkedIn share with facebook
All news about REGENXBIO INC.
09:50aREGENXBIO : to Host Conference Call on November 4 to Discuss Third Quarter 2020 ..
AQ
10/28REGENXBIO : To Host Conference Call on November 4 to Discuss Third Quarter 2020 ..
PR
10/28REGENXBIO : to Receive $80.0 Million Milestone Payment from Novartis AG
AQ
10/27REGENXBIO INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
09/28REGENXBIO : to Participate in Upcoming Investor Conferences
AQ
09/25REGENXBIO : to Participate in Upcoming Investor Conferences
PR
09/14Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential B..
PR
09/10CLEARSIDE BIOMEDICAL : Licensing Partner Doses First Patient in its Phase 2 Gene..
AQ
09/10REGENXBIO : Announces Dosing Of First Patient In Phase II AAVIATE Trial Of RGX-3..
AQ
09/02REGENXBIO : to Participate in Upcoming Investor Conferences
PR
More news